BioLine RX logo

BLRX - BioLine RX Share Price

$3.23 -0.3  -7.7%

Last Trade - 25/02/21

Sector
Healthcare
Size
Small Cap
Market Cap £105.1m
Enterprise Value £94.6m
Revenue £n/a
Position in Universe 4686th / 6709
Bullish
Bearish
Unlock BLRX Revenue
Momentum
Relative Strength (%)
1m +40.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 14.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BioLineRX Ltd revenues was not reported. Net loss increased 18% to$30M. Higher net loss reflects Change in fair value ofwarrants decrease from $4.6M (income) to $5.1M (expense),Interest income and exchange differences decrease of 70% to$236K (income), Issuance costs increase of 88% to $784K(expense). Basic Earnings per Share excluding ExtraordinaryItems increased from -$0.17 to -$0.12.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BLRX Revenue Unlock BLRX Revenue

Net Income

BLRX Net Income Unlock BLRX Revenue

Normalised EPS

BLRX Normalised EPS Unlock BLRX Revenue

PE Ratio Range

BLRX PE Ratio Range Unlock BLRX Revenue

Dividend Yield Range

BLRX Dividend Yield Range Unlock BLRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BLRX EPS Forecasts Unlock BLRX Revenue
Profile Summary

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 2, 2003
Public Since January 30, 2007
No. of Shareholders: n/a
No. of Employees: 48
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market (Dual Listing)
Shares in Issue 42,459,479
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BLRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BLRX
Upcoming Events for BLRX
Frequently Asked Questions for BioLine RX
What is the BioLine RX share price?

As of 25/02/21, shares in BioLine RX are trading at $3.23, giving the company a market capitalisation of £105.1m. This share price information is delayed by 15 minutes.

How has the BioLine RX share price performed this year?

Shares in BioLine RX are currently trading at $3.23 and the price has moved by 85.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioLine RX price has moved by 48.69% over the past year.

What are the analyst and broker recommendations for BioLine RX?

Of the analysts with advisory recommendations for BioLine RX, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioLine RX is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioLine RX next release its financial results?

BioLine RX is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the BioLine RX dividend yield?

BioLine RX does not currently pay a dividend.

Does BioLine RX pay a dividend?

BioLine RX does not currently pay a dividend.

When does BioLine RX next pay dividends?

BioLine RX does not currently pay a dividend.

How do I buy BioLine RX shares?

To buy shares in BioLine RX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioLine RX?

Shares in BioLine RX are currently trading at $3.23, giving the company a market capitalisation of £105.1m.

Where are BioLine RX shares listed? Where are BioLine RX shares listed?

Here are the trading details for BioLine RX:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BLRX
What kind of share is BioLine RX?

Based on an overall assessment of its quality, value and momentum, BioLine RX is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioLine RX share price forecast 2021?

Shares in BioLine RX are currently priced at $3.23. At that level they are trading at 1.56% discount to the analyst consensus target price of 0.00.

Analysts covering BioLine RX currently have a consensus Earnings Per Share (EPS) forecast of -20.6769386379 for the next financial year.

How can I tell whether the BioLine RX share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioLine RX. Over the past six months, the relative strength of its shares against the market has been 66.13%. At the current price of $3.23, shares in BioLine RX are trading at 61.42% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioLine RX PE Ratio?

We were not able to find PE ratio data for BioLine RX.

Who are the key directors of BioLine RX?

BioLine RX's management team is headed by:

Aharon Schwartz - CHM
Raphael Hofstein - DRC
Nurit Benjamini - NED
Michael Anghel - DRC
Philip Serlin - CEO
Sandra Panem - DRC
Mali Zeevi - CFO
Hillit Mannor Shachar - VBD
Ella Sorani - VPR
Abi Vainstein-Haras - VPR
Barbara-Jean Bormann - DRC
Who are the major shareholders of BioLine RX?

Here are the top five shareholders of BioLine RX based on the size of their shareholding:

Altium Capital Management LP Investment Advisor/Hedge Fund
Percentage owned: 4.01% (1.70m shares)
Sabby Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 2.74% (1.16m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 2.44% (1.04m shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 1.54% (655k shares)
Parkman Healthcare Partners LLC Hedge Fund
Percentage owned: 1.01% (428k shares)
Similar to BLRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.